Profile data is unavailable for this security.
About the company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.
- Revenue in USD (TTM)0.00
- Net income in USD-40.10m
- Incorporated2015
- Employees80.00
- LocationMustang Bio Inc377 PLANTATION STREETWORCESTER 01605United StatesUSA
- Phone+1 (781) 652-4500
- Fax+1 (302) 531-3150
- Websitehttps://www.mustangbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell MedX Corp | 70.00 | -96.91k | 9.87m | 0.00 | -- | -- | -- | 140,975.00 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -29.98m | 10.03m | 41.00 | -- | -- | -- | -- | -0.6765 | -0.6765 | 0.00 | -0.4079 | 0.00 | -- | -- | 0.00 | -382.78 | -- | -- | -- | -- | -- | -- | -- | -- | -27.45 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Imunon Inc | 0.00 | -18.85m | 10.06m | 33.00 | -- | 1.18 | -- | -- | -2.02 | -2.02 | 0.00 | 0.9041 | 0.00 | -- | -- | 0.00 | -66.82 | -50.18 | -91.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Mira Pharmaceuticals Inc | 0.00 | -12.36m | 10.49m | 3.00 | -- | 3.32 | -- | -- | -0.8276 | -0.8276 | 0.00 | 0.2136 | 0.00 | -- | -- | 0.00 | -587.64 | -- | -1,721.90 | -- | -- | -- | -- | -- | -- | -2.63 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
| Eterna Therapeutics Inc | 115.00k | -22.92m | 10.51m | 8.00 | -- | -- | -- | 91.43 | -4.25 | -4.25 | 0.0214 | -0.6307 | 0.0036 | -- | 0.2305 | 14,375.00 | -70.71 | -169.05 | -88.77 | -223.00 | -114.78 | -- | -19,912.17 | -682.61 | -- | -15.55 | 1.64 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Mustang Bio Inc | 0.00 | -40.10m | 10.64m | 80.00 | -- | -- | -- | -- | -4.55 | -4.55 | 0.00 | -0.4757 | 0.00 | -- | -- | 0.00 | -90.93 | -70.02 | -138.05 | -79.98 | -- | -- | -- | -- | -- | -15.88 | -- | -- | -- | -- | 33.44 | -- | -60.75 | -- |
| Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 10.66m | 20.00 | -- | -- | -- | 820.20 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
| NLS Pharmaceutics AG | 0.00 | -12.17m | 10.69m | 3.00 | -- | -- | -- | -- | -0.3188 | -0.3188 | 0.00 | -0.2724 | 0.00 | -- | -- | 0.00 | -218.86 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -81.34 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 195.98k | -19.20m | 10.75m | 8.00 | -- | 1.42 | -- | 54.86 | -3.38 | -3.38 | 0.034 | 1.05 | 0.01 | -- | 6.08 | 24,497.50 | -97.88 | -66.49 | -118.76 | -85.55 | -- | -- | -9,797.30 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Plus Therapeutics Inc (USA) | 6.08m | -11.77m | 11.01m | 20.00 | -- | -- | -- | 1.81 | -3.19 | -3.19 | 1.67 | -1.13 | 0.5724 | -- | -- | 304,200.00 | -110.75 | -59.18 | -- | -133.04 | -- | -- | -193.49 | -470.45 | -- | -- | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Energy Finders Inc | 4.06m | -2.92m | 11.07m | 46.00 | -- | -- | -- | 2.72 | -0.272 | -0.272 | 1.52 | 3.04 | -- | -- | -- | 88,304.35 | -- | -- | -- | -- | 27.45 | -- | -71.79 | -- | 0.6706 | -12.57 | 0.564 | -- | -- | -- | -- | -- | -- | -- |
| Enzon Pharmaceuticals Inc | 0.00 | 221.00k | 11.13m | 0.00 | 50.34 | 3.38 | -- | -- | 0.003 | 0.003 | 0.00 | 0.624 | 0.00 | -- | -- | -- | 3.21 | -0.8654 | 3.24 | -0.8851 | -- | -- | -- | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
| ELEVAI Labs Inc | 2.18m | -4.62m | 11.15m | 18.00 | -- | 4.11 | -- | 5.10 | -0.2665 | -0.2665 | 0.126 | 0.1435 | -- | -- | -- | 121,351.70 | -- | -- | -- | -- | 67.84 | -- | -211.42 | -- | 1.80 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| Senti Biosciences Inc | 1.28m | -86.11m | 11.29m | 48.00 | -- | 0.201 | -- | 8.85 | -1.93 | -1.44 | 0.0285 | 1.23 | 0.0097 | -- | 2.94 | 26,562.50 | -65.33 | -- | -71.42 | -- | -- | -- | -6,753.80 | -- | -- | -- | 0.0018 | -- | -40.25 | -- | -67.94 | -- | -- | -- |
Data as of Jun 18 2024. Currency figures normalised to Mustang Bio Inc's reporting currency: US Dollar USD
6.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 210.00k | 1.80% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 203.71k | 1.75% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 98.48k | 0.84% |
| Koss-Olinger Consulting LLCas of 31 Dec 2023 | 96.37k | 0.83% |
| Geode Capital Management LLCas of 31 Mar 2024 | 48.40k | 0.42% |
| Antecedo Asset Management GmbHas of 31 Dec 2023 | 46.67k | 0.40% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 35.39k | 0.30% |
| Virtu Americas LLCas of 31 Mar 2024 | 30.18k | 0.26% |
| HighTower Advisors LLCas of 31 Mar 2024 | 19.71k | 0.17% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 17.04k | 0.15% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
